301507SZSE

Progress Announcement on the Second Phase of Share Buyback via Centralized Bidding

✨ AI Summary

This announcement details the progress of Hangzhou Minsheng Health Pharmaceutical Co., Ltd.'s second phase of share buyback. As of March 31, 2026, the company has repurchased 2,105,100 shares, representing 0.59% of its total share capital, at a total cost of 31,476,595 RMB. The buyback is intended for equity incentives and complies with relevant regulations.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.

Important Content Reminder:

  • Implementation status of the second phase buyback plan: As of March 31, 2026, Hangzhou Minsheng Health Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") has cumulatively repurchased 2,105,100 shares through a dedicated securities account via centralized bidding, accounting for 0.59% of the company's total share capital. The highest transaction price was 15.67 RMB/share, the lowest transaction price was 14.22 RMB/share, and the total payment amount was 31,476,595 RMB (excluding transaction fees).

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.